Prevalence of Cannabidiol (CBD) Use Among Patients Taking Medications with Known Drug–Drug Interactions: A Cross-Sectional Analysis
Journal of Clinical Medicine · 02.11.2025 · 14 (21) · 7776
DOI: 10.3390/jcm14217776 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift Journal of Clinical Medicine, online erschienen am 02.11.2025. Verfasst von Hunter Geneau und 8 weiteren Autor:innen. Beteiligte Einrichtung: Brody School of Medicine, East Carolina University, Greenville, NC 27834, USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Cannabidiol (CBD) is widely available over the counter for presumed medical and recreational purposes. Despite its non-psychoactive nature, CBD exhibits intrinsic pharmacological activity that may lead to potential adverse drug events (ADEs) and drug–drug interactions (DDI) with common prescription medications through cytochrome P450 inhibition. Due to their largely unregulated nature and widespread advertising, consumers who use CBD products may not be aware of these potential negative drug interactions. The purpose of this study was to determine how frequently patients who use CBD products concurrently take prescription medication with known drug–drug interaction (DDI) potential, and to identify specific therapeutic classes most commonly involved.
Methods
In this cross-sectional study, a survey was distributed to patients and family members in the adult and pediatric Emergency Departments of a Level 1 Trauma Center in eastern North Carolina. Respondents reported household CBD use and selected from a list of conditions for which they take prescription medications.
Results
Of 681 eligible respondents, 254 (37.3%) reported CBD use in their household (CBDUIH). Among those with CBDUIH, 69.7% reported concurrent use of 1 or more medications with a potential DDI risk. The most common categories of prescriptions were antidepressants (64.4%) and antihypertensives (41.8%), followed by agents for diabetes, hyperlipidemia, and immune disorders.
Conclusions
The majority of CBD users in this population are concurrently taking medications with DDI potential, highlighting the need for patient and provider education, and improved labeling of CBD-based products to accurately reflect risks. Further study of clinically significant interactions is needed to determine which medications within these common categories have the most substantial risk of DDI.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Brody School of Medicine, East Carolina University, Greenville, NC 27834, USA.
ORCID-Profile: Michael McFayden, Kori Brewer
Zitieren
APA
Geneau, H., Kovasala, M., Brown, G., Holmes, S., Hime, O., McNally, M., McFayden, M., Brewer, K., & Jones, G. K. (2025). Prevalence of Cannabidiol (CBD) Use Among Patients Taking Medications with Known Drug–Drug Interactions: A Cross-Sectional Analysis. Journal of Clinical Medicine, 14(21), 7776. https://doi.org/10.3390/jcm14217776
Vancouver
Geneau H, Kovasala M, Brown G, Holmes S, Hime O, McNally M, et al. Prevalence of Cannabidiol (CBD) Use Among Patients Taking Medications with Known Drug–Drug Interactions: A Cross-Sectional Analysis. Journal of Clinical Medicine. 2025;14(21):7776. doi:10.3390/jcm14217776
BibTeX
@article{Geneau2025,
author = {Geneau, Hunter and Kovasala, Michael and Brown, Grant and Holmes, Simeon and Hime, Olivia and McNally, Michael and McFayden, Michael and Brewer, Kori and Jones, G Kirk},
title = {Prevalence of Cannabidiol (CBD) Use Among Patients Taking Medications with Known Drug–Drug Interactions: A Cross-Sectional Analysis},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {21},
pages = {7776},
doi = {10.3390/jcm14217776}
}
EUVIMED